Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hamon

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Human Heredity|May 20, 2006
Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene clusterSara C Hamon, Sharon L R Kardia, Eric Boerwinkle, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 10, 2006
Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participantsKathy L E Klos, Charles F Sing, Eric Boerwinkle, et al.
Clinical Biochemistry|August 1, 1995
Fatty acids and plasma antioxidants in HIV-positive patients: correlation with nutritional and immunological statusJ Constans, E Peuchant, J L Pellegrin, et al.
Psychiatric Genetics|June 8, 2017
Genetic moderation of cocaine subjective effects by variation in the TPH1, TPH2, and SLC6A4 serotonin genesMichelle A Patriquin, Sara C Hamon, Mark J Harding, et al.
Frontiers in Psychiatry|June 20, 2012
Forced Abstinence from Cocaine Self-Administration is Associated with DNA Methylation Changes in Myelin Genes in the Corpus Callosum: a Preliminary StudyDavid A Nielsen, Wen Huang, Sara C Hamon, et al.
Journal of Lipid Research|December 1, 2005
Contribution of regulatory and structural variations in APOE to predicting dyslipidemiaJari H Stengård, Sharon L R Kardia, Sara C Hamon, et al.
The American Journal on Addictions|May 16, 2019
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addictionJune P Kampangkaew, Catherine J Spellicy, Ellen M Nielsen, et al.
Immunogenetics|January 1, 1996
The RAG cell line defines a new complementation group of MHC class II deficiencyA Lennon, C Ottone, A Peijnenburg, et al.
Psychiatric Genetics|May 6, 2021
The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patientsPatrick S Thomas, Ellen M Nielsen, Catherine J Spellicy, et al.
Journal of Clinical Lipidology|October 2, 2017
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemiaJoep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Human Heredity|May 20, 2006
Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene clusterSara C Hamon, Sharon L R Kardia, Eric Boerwinkle, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 10, 2006
Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participantsKathy L E Klos, Charles F Sing, Eric Boerwinkle, et al.
Clinical Biochemistry|August 1, 1995
Fatty acids and plasma antioxidants in HIV-positive patients: correlation with nutritional and immunological statusJ Constans, E Peuchant, J L Pellegrin, et al.
Psychiatric Genetics|June 8, 2017
Genetic moderation of cocaine subjective effects by variation in the TPH1, TPH2, and SLC6A4 serotonin genesMichelle A Patriquin, Sara C Hamon, Mark J Harding, et al.
Frontiers in Psychiatry|June 20, 2012
Forced Abstinence from Cocaine Self-Administration is Associated with DNA Methylation Changes in Myelin Genes in the Corpus Callosum: a Preliminary StudyDavid A Nielsen, Wen Huang, Sara C Hamon, et al.
Journal of Lipid Research|December 1, 2005
Contribution of regulatory and structural variations in APOE to predicting dyslipidemiaJari H Stengård, Sharon L R Kardia, Sara C Hamon, et al.
The American Journal on Addictions|May 16, 2019
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addictionJune P Kampangkaew, Catherine J Spellicy, Ellen M Nielsen, et al.
Immunogenetics|January 1, 1996
The RAG cell line defines a new complementation group of MHC class II deficiencyA Lennon, C Ottone, A Peijnenburg, et al.
Psychiatric Genetics|May 6, 2021
The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patientsPatrick S Thomas, Ellen M Nielsen, Catherine J Spellicy, et al.
Journal of Clinical Lipidology|October 2, 2017
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemiaJoep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
Pageof 10